A lipid boundary separates APP and secretases and limits amyloid β-peptide generation
Authors:
Open Access
- 6 December 2004
- journal article
- editorial
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 167 (5) , 809-812
Abstract
Millions of patients suffer from Alzheimer's disease, and intensive efforts to find a cure for this devastating disorder center on the proteases, which release the deadly amyloid β-peptide from its precursor. The cutting procedure is thought to be cholesterol dependent and strategies to lower cholesterol as therapeutic treatment are under intensive investigation. Recent findings suggest that the complete proteolytic machinery required for amyloid β-peptide generation is located within lipid rafts. Data by Dotti and colleagues (Abad-Rodriguez et al., 2004), in this issue, suggest that rafts isolate the cutting machinery away from its deadly substrate. These findings describe a novel mechanism for controlling proteolytic activity by building a lipid boundary between proteases and their substrates.Keywords
This publication has 20 references indexed in Scilit:
- Neuronal membrane cholesterol loss enhances amyloid peptide generationJournal of Cell Biology, 2004
- The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's DiseaseNeuron, 2004
- Dimeric Amyloid β Protein Rapidly Accumulates in Lipid Rafts followed by Apolipoprotein E and Phosphorylated Tau Accumulation in the Tg2576 Mouse Model of Alzheimer's DiseaseThe Journal of Neuroscience, 2004
- Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generationThe EMBO Journal, 2004
- Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid raftsJournal of Cell Biology, 2003
- Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10Proceedings of the National Academy of Sciences, 2001
- Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivoProceedings of the National Academy of Sciences, 2001
- Elevated Low-Density Lipoprotein in Alzheimer's Disease Correlates with Brain Aβ 1–42 LevelsBiochemical and Biophysical Research Communications, 1998
- The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathwayNature Medicine, 1995
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993